Estraflex® CMO (Cetylated Fatty Acids)

Estraflex® CMO supplies cetylated fatty acids, a group of fats including cetyl myristoleate (CMO) studied for joint health. In one small controlled trial, a generic cetylated fatty acid product (Celadrin, not the Estraflex brand) improved knee function in people with osteoarthritis.

Estraflex CMO is researched primarily for Joint Health. In one small 68 day trial of 64 adults, a generic cetylated fatty acid product improved knee flexion and Lequesne function scores versus placebo. This is the only controlled trial, and it did not test the Estraflex brand.

The clinically studied dose is Commonly around 350 to 500 mg of cetylated fatty acids per day. Always follow the product label and check with a healthcare provider for personal advice.

For most healthy adults, Estraflex CMO is well tolerated at studied doses. Reported effects can include: Generally well-tolerated — adverse effects are uncommon at normal doses. Mild digestive upset is occasionally reported. It may also interact with some medications. Estraflex CMO is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Possible interactions include: No major drug interactions are established for this ingredient. Tell your doctor about all supplements if you take prescription medication. If you take prescription medication, check with a pharmacist or doctor before using it.

NutraSmarts rates the evidence for Estraflex CMO as Limited (2 out of 5). It is backed by 1 clinical trial and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.